查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190734

空胶囊市场——增长、趋势、COVID-19 的影响和预测 (2023-2028)

Empty Capsules Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，空心胶囊市场预计将以 7.4% 的复合年增长率增长。

预计 COVID-19 大流行将对市场增长产生积极影响。 由于增强免疫力的发展在对抗病毒感染方面发挥着重要作用，因此对天然草药和膳食补充剂形式的免疫增强剂的需求不断增长。 除基本卫生外，适当的饮食和生活方式对于预防和治疗 COVID-19 等呼吸道病毒性疾病至关重要。 根据 2020 年发表的一篇研究论文，所有 COVID-19 患者都应在入院时接受营养不良筛查并评估血清维生素 D 水平。 此外，2020 年 3 月，Stabiltech BioPharma Ltd 开发了一种用于注射 COVID-19 疫苗的新型口服胶囊。 因此，预计 COVID-19 大流行将增加对膳食补充剂的需求并促进市场增长。

推动市场增长的关键因素包括胶囊比其他给药形式越来越受欢迎，以及空胶囊供应商和明胶製造商之间的战略合作伙伴关係不断加强。 此外，世界人口老龄化加剧，增加了对各种治疗药物和营养补充剂的需求，以实现更好的健康。 根据联合国世界老龄化人口：2020 年修订版，到 2050 年将有约 15 亿人超过 65 岁，高于 2020 年的 7.27 亿。 此外，胶囊输送技术的快速进步有望补充市场增长。 然而，道德问题、明胶材料的价格波动以及製药行业的严格法规预计将阻碍市场增长。

主要市场趋势

心血管治疗领域有望在预测期内实现健康的复合年增长率

心血管疾病 (CVD) 在世界范围内高发。 根据世界卫生组织 2019 年的数据，全球每年估计有 1790 万人死于心血管疾病，预计到 2030 年这一数字将增加到 2360 万以上。 此外，根据美国心臟协会 2020 年调查报告，心血管疾病被列为根本死因，每天在美国造成约 2,353 人死亡，平均每 37 秒就有 1 人死亡。 根据英国心臟基金会中心的数据，到 2021 年，英国约有 760 万人患有心臟和循环系统疾病。 在英国，每年有超过 40,000 名 75 岁以下的人死于心臟和循环系统疾病。 全球范围内心血管疾病的流行增加了对心血管治疗药物有效治疗的需求，从而促进了市场的增长。

此外，在 COVID-19 流行期间，美国心脏病学会和加拿大心脏病学会提倡心臟干预，例如通过运动训练和饮食咨询进行家庭心臟康復、药物管理、戒烟咨询和社会心理评估干预。公布了重新引入服务的指南。 因此，预计心臟康復课程的增加将在 COVID-19 流行期间推动研究领域的发展。

2019 年 9 月，Lupin 还获得了加拿大卫生监管机构的批准，用于治疗高血压和减轻心绞痛的盐酸普□洛尔缓释胶囊。 预计增加产品批准也将在预测期内推动这一细分市场。

空胶囊可有效掩盖心臟药物的味道并防止患者感到噁心。 因此，随着 CVD 患病率的上升，对心臟药物的需求也会增加。 这一因素可能会对空心胶囊市场产生积极影响。

北美占据了很大的市场份额，预计在预测期内将继续保持这一势头

由于人们越来越偏爱基于胶囊的膳食补充剂配方，该地区占据了主要份额。 这些膳食补充剂的消费量正在增加，因为它们有助于预防肥胖、癌症和关节炎等重大健康问题。 此外，该地区营养补充剂行业对空胶囊的需求很高，因为胶囊是最受欢迎的固体口服剂型。

此外，随着美国人口老龄化，慢性病负担的加重也被认为是北美市场增长的主要因素。 根据人口事务研究所的美国人口公报 - 老龄化，预计到 2060 年，65 岁及以上的美国人数量将从 2018 年的 5200 万增加近一倍至 9500 万。 同样，2019 年 CRN 膳食补充剂消费者调查的一份报告发现，77% 的美国人表示他们服用膳食补充剂。 调查还发现，维生素和矿物质是 2019 年美国人最常食用的补充剂，占所有膳食补充剂的 76%，其次是专业补充剂 (40%)、草药和植物 (39%)、运动营养补充剂 (28 %) 和体重管理补充剂 (17%)。

但是，在 COVID-19 大流行期间，大多数肉类加工设施都关闭了，限制了明胶的供应。 此外，由于国际边界的运输限制，预计北美将对明胶胶囊的供应链产生严重影响，阻碍该地区的市场增长。

此外，美国和加拿大还开发和构建了鼓励研究和开发的医疗保健系统。 它还鼓励全球公司进入美国和加拿大。 因此，这些国家将有许多世界球员。 由于全球公司在该地区的存在满足了高需求，预计该市场将在预测期内进一步增长。

竞争格局

大部分空心胶囊由世界领先的公司生产。 拥有更多研究资金和更好的分销系统的市场领导者正在市场中站稳脚跟。 空心胶囊市场高度整合，由 ACG Worldwide、Medi-Caps Ltd、LonzaGroup (Capsugel)、Capscanada Corporation、Bright Pharma Caps Inc 等几家主要参与者组成。 由于空心胶囊意识的增强，亚太地区也出现了一些中小型玩家。 此外，主要参与者正在参与战略联盟和产品发布，以确保他们在竞争市场中的地位。 例如，2020 年 10 月，龙沙 (Lonza) 向其胶囊和保健成分 (CHI) 部门投资 8500 万瑞士法郎，以将其胶囊製造能力扩大到每年 300 亿粒胶囊。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 增加製药应用
    • 空心胶囊技术进展
    • 老年人口增加
  • 市场製约因素
    • 明胶价格上涨，原材料获取困难
    • 文化习俗和饮食限制
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品分类
    • 明胶胶囊
    • 非明胶胶囊
  • 职能性别
    • 速释胶囊
    • 缓释胶囊
    • 缓释胶囊
  • 通过使用
    • 抗生素和抗菌剂
    • 维生素和营养补充剂
    • 抗酸药和抗胀气药
    • 心血管药物
    • 其他治疗用途
  • 最终用户
    • 医药行业
    • 营养保健品
    • 化妆品行业
    • 研究所
  • 区域信息
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • ACG Worldwide
    • Bright Pharma Caps Inc.
    • Capscanada Corporation
    • Lonza Group（Capsugel）
    • Medi-Caps Ltd
    • Qualicaps
    • Suheung Capsule Co. Ltd
    • Qingdao Yiqing Medicinal Capsules Co. Ltd
    • Shanxi Guangsheng Medicinal Capsules Co. Ltd
    • Healthcaps India Ltd
    • Nectar Lifesciences Ltd
    • Shanxi JC Biological Technology Co. Ltd

第7章 市场机会今后动向

简介目录
Product Code: 64988

The empty capsules market is expected to record a CAGR of 7.4% over the forecast period.

The COVID-19 pandemic is expected to positively impact the market's growth. As the development of strong immunity plays a vital role in fighting against viral infection, there has been an increasing demand for immunity boosters in the form of natural herbs and nutraceuticals. Apart from the basic hygienic practices, proper dietary and lifestyle behaviors are essential for preventing and treating respiratory viral diseases, such as COVID-19. As per the research article published in 2020, every COVID-19 patient should be screened for malnutrition on admission and assessed for serum vitamin D levels. Additionally, in March 2020, Stabilitech BioPharma Ltd developed a new oral capsule to deliver the COVID-19 vaccine. Thus, the COVID-19 pandemic is boosting the demand for nutraceuticals, which is expected to help the market to grow.

The key factors that boost the market's growth include a rise in the popularity of capsules over other drug delivery forms and an increase in strategic collaborations between empty capsule suppliers and gelatin manufacturers. Also, the growing geriatric population worldwide increases the demand for various therapy drugs and dietary supplements for better health outcomes. According to the United Nations, World Ageing Population: the 2020 Revision, by 2050, approximately 1.5 billion people are likely to be over 65 years, up from 727 million in 2020. In addition, rapid advancements in capsule delivery technologies are set to supplement the market's growth. However, ethical concerns, price fluctuations regarding gelatin materials, and stringent regulations in the pharmaceutical industry are expected to hamper the market growth.

Key Market Trends

The Cardiovascular Therapy Drugs Segment is Expected to Witness a Healthy CAGR Over the Forecast Period

Cardiovascular diseases (CVD) are highly prevalent globally. According to the World Health Organization 2019, an estimated 17.9 million people die due to cardiovascular diseases worldwide each year, and the number is expected to grow to more than 23.6 million by 2030. Additionally, as per the American Heart Association Research Report 2020, cardiovascular disease, listed as the underlying cause of death, accounts for nearly 2,353 deaths daily in United States, which is an average of 1 death every 37 seconds. Also, according to the British Heart Foundation Centre, 2021, around 7.6 million people were living with heart and circulatory diseases in United Kingdom. More than 40,000 people under the age of 75 years in United Kingdom die from heart and circulatory diseases each year. The high incidence of cardiovascular diseases worldwide surges the demand for cardiovascular therapy drugs for effective treatment, thus driving the market's growth.

Additionally, during the COVID-19 pandemic, the American College of Cardiology and the Canadian Cardiovascular Society issued guidelines for the reintroduction of cardiac services, including home-based cardiac rehabilitation that provide exercise training and dietary counseling, medication management, tobacco cessation counseling, and psychosocial assessment interventions. Hence, the increasing cardiac rehabilitation sessions are expected to boost the studied segment during the COVID-19 pandemic.

Also, in September 2019, Lupin received approval from the Canadian health regulator for its Propranolol Hydrochloride extended-release capsules used to treat hypertension and decreased frequency of angina. The increasing product approvals are also expected to boost the segment over the forecast period.

Empty capsules are useful in masking the taste of cardiac therapy drugs, which prevents the patient from feeling nauseated. Hence, as the prevalence of CVDs increases, the demand for cardiac therapy drugs will also increase. This factor may positively impact the empty capsules market.

North America Holds a Significant Share in the Market and is Expected to Continue the Trend over the Forecast Period

The region holds a major share due to the rising preference for capsule-based nutraceutical formulations. Since these nutraceuticals help prevent major health problems, such as obesity, cancer, and arthritis, their consumption has increased. Additionally, capsules are the most preferred solid oral dosage forms, and thus, the demand for empty capsules in the nutraceutical industry is high in the region.

Also, the growing burden of chronic diseases, along with the rising geriatric population in United States, is considered a major factor for the growth of the market in North America. According to the Population Reference Bureau's Population Bulletin-Aging in United States, the number of Americans aged 65 years and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. Similarly, as per the CRN Consumer Survey on Dietary Supplements, 2019 report, 77% of Americans reported consuming dietary supplements. Also, the survey revealed that vitamins and minerals were the most common supplements consumed by the American population in 2019, accounting for 76% of total dietary supplement consumption, followed by specialty supplements (40%), herbals and botanicals (39%), sports nutrition supplements (28%), and weight management supplements (17 %) in 2019.

However, during the COVID-19 pandemic, most meat processing facilities were shut down, which limited the availability of gelatin. Additionally, due to the transport restrictions in the borders of various countries worldwide, North America is expected to be severely impacted on the supply chain of the gelatin capsule, which is expected to hamper the market's growth in the region.

Moreover, United States and Canada have a developed and well-structured healthcare system, which encourages research and development. They also encourage global players to enter United States and Canada. As a result, these countries enjoy the presence of many global market players. As the high demand is met by the presence of global players in the region, the market is further expected to grow over the forecast period.

Competitive Landscape

Global key players are manufacturing the majority of empty capsules. Market leaders with more funds for research and a better distribution system have established their positions in the market. The empty capsules market is highly consolidated and consists of a few major players, including ACG Worldwide, Medi-Caps Ltd, LonzaGroup (Capsugel), Capscanada Corporation, and Bright Pharma Caps Inc. Moreover, Asia-Pacific is witnessing the emergence of a few small- and medium-sized players due to the rising awareness of empty capsules. Additionally, key players are involved in strategic alliances and product launches to secure their positions in the competitive market. For instance, in October 2020, Lonza invested CHF 85 million in its Capsules and Health Ingredients (CHI) division to expand its capsule manufacturing capacity by 30 billion capsules annually.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Pharmaceutical Applications
    • 4.2.2 Technological Advancements in Empty Capsules
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Rising Gelatin Prices and Lower Availability of Raw Materials
    • 4.3.2 Cultural Practices and Dietary Restrictions
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Gelatin Capsules
    • 5.1.2 Non-gelatin Capsules
  • 5.2 By Functionality
    • 5.2.1 Immediate-release Capsules
    • 5.2.2 Delayed-release Capsules
    • 5.2.3 Sustained-release Capsules
  • 5.3 By Therapeutic Application
    • 5.3.1 Antibiotic and Antibacterial Drugs
    • 5.3.2 Vitamins and Dietary Supplements
    • 5.3.3 Antacid and Antiflatulent Preparations
    • 5.3.4 Cardiovascular Therapy Drugs
    • 5.3.5 Other Therapeutic Applications
  • 5.4 By End User
    • 5.4.1 Pharmaceutical Industry
    • 5.4.2 Nutraceutical Industry
    • 5.4.3 Cosmetics Industry
    • 5.4.4 Research Laboratories
  • 5.5 By Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ACG Worldwide
    • 6.1.2 Bright Pharma Caps Inc.
    • 6.1.3 Capscanada Corporation
    • 6.1.4 Lonza Group (Capsugel)
    • 6.1.5 Medi-Caps Ltd
    • 6.1.6 Qualicaps
    • 6.1.7 Suheung Capsule Co. Ltd
    • 6.1.8 Qingdao Yiqing Medicinal Capsules Co. Ltd
    • 6.1.9 Shanxi Guangsheng Medicinal Capsules Co. Ltd
    • 6.1.10 Healthcaps India Ltd
    • 6.1.11 Nectar Lifesciences Ltd
    • 6.1.12 Shanxi JC Biological Technology Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS